Huang YY, Zhang XY, Zhu P, Ji L. Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications. World J Clin Cases 2022; 10(18): 5934-5945 [PMID: 35949837 DOI: 10.12998/wjcc.v10.i18.5934]
Corresponding Author of This Article
Ling Ji, Doctor, Chief Technician, Department of Laboratory Medicine, Peking University Shenzhen Hospital, No. 1120 Lianhua Road, Futian District, Shenzhen 518035, Guangdong Province, China. 1120303921@qq.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2022; 10(18): 5934-5945 Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.5934
Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications
Yue-Ying Huang, Xiao-Yu Zhang, Ping Zhu, Ling Ji
Yue-Ying Huang, Xiao-Yu Zhang, Ping Zhu, School of Medical Laboratory, Weifang Medical University, Weifang 261053, Shandong Province, China
Ling Ji, Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen 518035, Guangdong Province, China
Author contributions: Huang YY contributed to the conception of the study; Zhang XY designed the work; Zhu P contributed to the acquisition of the case; Ji L revised the manuscript critically for important intellectual content; all authors have read the manuscript and gave their final approval of the version to be published.
Supported bythe Shenzhen Science and Technology R&D Fund, No. JCYJ20190809095203586.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ling Ji, Doctor, Chief Technician, Department of Laboratory Medicine, Peking University Shenzhen Hospital, No. 1120 Lianhua Road, Futian District, Shenzhen 518035, Guangdong Province, China. 1120303921@qq.com
Received: November 3, 2021 Peer-review started: November 3, 2021 First decision: December 27, 2021 Revised: January 10, 2022 Accepted: April 24, 2022 Article in press: April 24, 2022 Published online: June 26, 2022 Processing time: 225 Days and 18.5 Hours
Abstract
The clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) proteins constitute the innate adaptive immune system in several bacteria and archaea. This immune system helps them in resisting the invasion of phages and foreign DNA by providing sequence-specific acquired immunity. Owing to the numerous advantages such as ease of use, low cost, high efficiency, good accuracy, and a diverse range of applications, the CRISPR-Cas system has become the most widely used genome editing technology. Hence, the advent of the CRISPR/Cas technology highlights a tremendous potential in clinical diagnosis and could become a powerful asset for modern medicine. This study reviews the recently reported application platforms for screening, diagnosis, and treatment of different diseases based on CRISPR/Cas systems. The limitations, current challenges, and future prospectus are summarized; this article would be a valuable reference for future genome-editing practices.
Core Tip: This review mainly discusses and explores the potential clinical applications of the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) technology. The detection technologies for nucleic acids and small molecules of different pathogens based on the CRISPR/Cas system are summarized. The advantages and disadvantages of the CRISPR/Cas technology from the aspects of gene editing, disease treatment, multi-drug resistance, and treatment are enumerated, asserting that CRISPR/Cas system has unlimited potential in clinical applications with certain challenges.
